Summary

Kidney Cancer Diagnostics Market – Scope of Report
TMR’s report on the global kidney cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kidney cancer diagnostics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kidney cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the kidney cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kidney cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kidney cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kidney cancer diagnostics market.

The report delves into the competitive landscape of the global kidney cancer diagnostics market. Key players operating in the global kidney cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kidney cancer diagnostics market profiled in this report.

Key Questions Answered in Global kidney cancer diagnostics Market Report
• What is the sales/revenue generated by kidney cancer diagnostics across all regions during the forecast period?
• What are the opportunities in the global kidney cancer diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Kidney Cancer Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global kidney cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kidney cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kidney cancer diagnostics market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Kidney Cancer Diagnostics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Kidney Cancer Diagnostics Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Product Type
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Product Type, 2020-2034
        6.3.1. Platform-based Products
        6.3.2. Instrument-based Products
        6.3.3. Kits and Reagents
        6.3.4. Others (Consumables, etc.)
    6.4. Market Attractiveness, by Product Type
7. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Test Type
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Test Type, 2020-2034
        7.3.1. Biopsy
        7.3.2. Imaging Tests
        7.3.3. Blood Tests
        7.3.4. Others (Genetic Testing, etc.)
    7.4. Market Attractiveness, by Test Type
8. Global Kidney Cancer Diagnostics Market Analysis and Forecast, By Cancer Stage
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, By Cancer Stage, 2020-2034
        8.3.1. Stage 1
        8.3.2. Stage 2
        8.3.3. Stage 3
        8.3.4. Stage 4
    8.4. Market Attractiveness, By Cancer Stage
9. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Tumor Type
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by Tumor Type, 2020-2034
        9.3.1. Renal Cell Carcinoma
        9.3.2. Clear Cell Carcinoma
        9.3.3. Non-clear Cell Carcinoma
    9.4. Market Attractiveness, by Tumor Type
10. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Technology
    10.1. Introduction and Definitions
    10.2. Key Findings/Developments
    10.3. Market Value Forecast, by Tumor Type, 2020-2034
        10.3.1. Fluorescent In Situ Hybridization
        10.3.2. Next Generation Sequencing
        10.3.3. Fluoroimmunoassay
        10.3.4. Comparative Genomic Hybridization
        10.3.5. Others (Immunohistochemical, etc.)
    10.4. Market Attractiveness, by Tumor Type
11. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by End-user
    11.1. Introduction and Definitions
    11.2. Key Findings/Developments
    11.3. Market Value Forecast, by End-user, 2020-2034
        11.3.1. Hospitals
        11.3.2. Cancer Research Centers
        11.3.3. Oncology Clinics
        11.3.4. Diagnostic Centers
        11.3.5. Ambulatory Surgery Centers
        11.3.6. Others (Research Institutes, etc.)
    11.4. Market Attractiveness, by End-user
12. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Region
    12.1. Key Findings
    12.2. Market Value Forecast, by Region, 2020-2034
        12.2.1. North America
        12.2.2. Europe
        12.2.3. Asia Pacific
        12.2.4. Latin America
        12.2.5. Middle East & Africa
    12.3. Market Attractiveness, by Region
13. North America Kidney Cancer Diagnostics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Product Type, 2020-2034
        13.2.1. Platform-based Products
        13.2.2. Instrument-based Products
        13.2.3. Kits and Reagents
        13.2.4. Others (Consumables, etc.)
    13.3. Market Attractiveness, by Product Type
    13.4. Market Value Forecast, by Test Type, 2020-2034
        13.4.1. Biopsy
        13.4.2. Imaging Tests
        13.4.3. Blood Tests
        13.4.4. Others (Genetic Testing, etc.)
    13.5. Market Attractiveness, by Test Type
    13.6. Market Value Forecast, By Cancer Stage, 2020-2034
        13.6.1. Stage 1
        13.6.2. Stage 2
        13.6.3. Stage 3
        13.6.4. Stage 4
    13.7. Market Attractiveness, By Cancer Stage
    13.8. Market Value Forecast, by Tumor Type, 2020-2034
        13.8.1. Renal Cell Carcinoma
        13.8.2. Clear Cell Carcinoma
        13.8.3. Non-clear Cell Carcinoma
    13.9. Market Attractiveness, by Tumor Type
    13.10. Market Value Forecast, by Technology 2020-2034
        13.10.1. Fluorescent In Situ Hybridization
        13.10.2. Next Generation Sequencing
        13.10.3. Fluoroimmunoassay
        13.10.4. Comparative Genomic Hybridization
        13.10.5. Others (Immunohistochemical, etc.)
    13.11. Market Attractiveness, by Technology
    13.12. Market Value Forecast, by End-user, 2020-2034
        13.12.1. Hospitals
        13.12.2. Cancer Research Centers
        13.12.3. Oncology Clinics
        13.12.4. Diagnostic Centers
        13.12.5. Ambulatory Surgery Centers
        13.12.6. Others (Research Institutes, etc.)
    13.13. Market Attractiveness, by End-user
    13.14. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.14.1. U.S.
        13.14.2. Canada
    13.15. Market Attractiveness Analysis
        13.15.1. By Product Type
        13.15.2. By Test Type
        13.15.3. By Cancer Stage
        13.15.4. By Tumor Type
        13.15.5. By End-user
        13.15.6. By Country
14. Europe Kidney Cancer Diagnostics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Product Type, 2020-2034
        14.2.1. Platform-based Products
        14.2.2. Instrument-based Products
        14.2.3. Kits and Reagents
        14.2.4. Others (Consumables, etc.)
    14.3. Market Attractiveness, by Product Type
    14.4. Market Value Forecast, by Test Type, 2020-2034
        14.4.1. Biopsy
        14.4.2. Imaging Tests
        14.4.3. Blood Tests
        14.4.4. Others (Genetic Testing, etc.)
    14.5. Market Attractiveness, by Test Type
    14.6. Market Value Forecast, By Cancer Stage, 2020-2034
        14.6.1. Stage 1
        14.6.2. Stage 2
        14.6.3. Stage 3
        14.6.4. Stage 4
    14.7. Market Attractiveness, By Cancer Stage
    14.8. Market Value Forecast, by Tumor Type, 2020-2034
        14.8.1. Renal Cell Carcinoma
        14.8.2. Clear Cell Carcinoma
        14.8.3. Non-clear Cell Carcinoma
    14.9. Market Attractiveness, by Tumor Type
    14.10. Market Value Forecast, by Technology, 2020-2034
        14.10.1. Fluorescent In Situ Hybridization
        14.10.2. Next Generation Sequencing
        14.10.3. Fluoroimmunoassay
        14.10.4. Comparative Genomic Hybridization
        14.10.5. Others (Immunohistochemical, etc.)
    14.11. Market Attractiveness, by Technology
    14.12. Market Value Forecast, by End-user, 2020-2034
        14.12.1. Hospitals
        14.12.2. Cancer Research Centers
        14.12.3. Oncology Clinics
        14.12.4. Diagnostic Centers
        14.12.5. Ambulatory Surgery Centers
        14.12.6. Others (Research Institutes, etc.)
    14.13. Market Attractiveness, by End-user
    14.14. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.14.1. Germany
        14.14.2. U.K.
        14.14.3. France
        14.14.4. Italy
        14.14.5. Spain
        14.14.6. Rest of Europe
    14.15. Market Attractiveness Analysis
        14.15.1. By Product Type
        14.15.2. By Test Type
        14.15.3. By Cancer Stage
        14.15.4. By Tumor Type
        14.15.5. By End-user
        14.15.6. By Country/Sub-region
15. Asia Pacific Kidney Cancer Diagnostics Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Product Type, 2020-2034
        15.2.1. Platform-based Products
        15.2.2. Instrument-based Products
        15.2.3. Kits and Reagents
        15.2.4. Others (Consumables, etc.)
    15.3. Market Attractiveness, by Product Type
    15.4. Market Value Forecast, by Test Type, 2020-2034
        15.4.1. Biopsy
        15.4.2. Imaging Tests
        15.4.3. Blood Tests
        15.4.4. Others (Genetic Testing, etc.)
    15.5. Market Attractiveness, by Test Type
    15.6. Market Value Forecast, By Cancer Stage, 2020-2034
        15.6.1. Stage 1
        15.6.2. Stage 2
        15.6.3. Stage 3
        15.6.4. Stage 4
    15.7. Market Attractiveness, By Cancer Stage
    15.8. Market Value Forecast, by Tumor Type, 2020-2034
        15.8.1. Renal Cell Carcinoma
        15.8.2. Clear Cell Carcinoma
        15.8.3. Non-clear Cell Carcinoma
    15.9. Market Attractiveness, by Tumor Type
    15.10. Market Value Forecast, by Technology 2020-2034
        15.10.1. Fluorescent In Situ Hybridization
        15.10.2. Next Generation Sequencing
        15.10.3. Fluoroimmunoassay
        15.10.4. Comparative Genomic Hybridization
        15.10.5. Others (Immunohistochemical, etc.)
    15.11. Market Attractiveness, by Technology
    15.12. Market Value Forecast, by End-user, 2020-2034
        15.12.1. Hospitals
        15.12.2. Cancer Research Centers
        15.12.3. Oncology Clinics
        15.12.4. Diagnostic Centers
        15.12.5. Ambulatory Surgery Centers
        15.12.6. Others (Research Institutes, etc.)
    15.13. Market Attractiveness, by End-user
    15.14. Market Value Forecast, by Country/Sub-region, 2020-2034
        15.14.1. China
        15.14.2. Japan
        15.14.3. India
        15.14.4. Australia & New Zealand
        15.14.5. Rest of Asia Pacific
    15.15. Market Attractiveness Analysis
        15.15.1. By Product Type
        15.15.2. By Test Type
        15.15.3. By Cancer Stage
        15.15.4. By Tumor Type
        15.15.5. By End-user
        15.15.6. By Country/Sub-region
16. Latin America Kidney Cancer Diagnostics Market Analysis and Forecast
    16.1. Introduction
        16.1.1. Key Findings
    16.2. Market Value Forecast, by Product Type, 2020-2034
        16.2.1. Platform-based Products
        16.2.2. Instrument-based Products
        16.2.3. Kits and Reagents
        16.2.4. Others (Consumables, etc.)
    16.3. Market Attractiveness, by Product Type
    16.4. Market Value Forecast, by Test Type, 2020-2034
        16.4.1. Biopsy
        16.4.2. Imaging Tests
        16.4.3. Blood Tests
        16.4.4. Others (Genetic Testing, etc.)
    16.5. Market Attractiveness, by Test Type
    16.6. Market Value Forecast, By Cancer Stage, 2020-2034
        16.6.1. Stage 1
        16.6.2. Stage 2
        16.6.3. Stage 3
        16.6.4. Stage 4
    16.7. Market Attractiveness, By Cancer Stage
    16.8. Market Value Forecast, by Tumor Type, 2020-2034
        16.8.1. Renal Cell Carcinoma
        16.8.2. Clear Cell Carcinoma
        16.8.3. Non-clear Cell Carcinoma
    16.9. Market Attractiveness, by Tumor Type
    16.10. Market Value Forecast, by Technology, 2020-2034
        16.10.1. Fluorescent In Situ Hybridization
        16.10.2. Next Generation Sequencing
        16.10.3. Fluoroimmunoassay
        16.10.4. Comparative Genomic Hybridization
        16.10.5. Others (Immunohistochemical, etc.)
    16.11. Market Attractiveness, by Technology
    16.12. Market Value Forecast, by End-user, 2020-2034
        16.12.1. Hospitals
        16.12.2. Cancer Research Centers
        16.12.3. Oncology Clinics
        16.12.4. Diagnostic Centers
        16.12.5. Ambulatory Surgery Centers
        16.12.6. Others (Research Institutes, etc.)
    16.13. Market Attractiveness, by End-user
    16.14. Market Value Forecast, by Country/Sub-region, 2020-2034
        16.14.1. Brazil
        16.14.2. Mexico
        16.14.3. Rest of Latin America
    16.15. Market Attractiveness Analysis
        16.15.1. By Product Type
        16.15.2. By Test Type
        16.15.3. By Cancer Stage
        16.15.4. By Tumor Type
        16.15.5. By End-user
        16.15.6. By Country/Sub-region
17. Middle East & Africa Kidney Cancer Diagnostics Market Analysis and Forecast
    17.1. Introduction
        17.1.1. Key Findings
    17.2. Market Value Forecast, by Product Type, 2020-2034
        17.2.1. Platform-based Products
        17.2.2. Instrument-based Products
        17.2.3. Kits and Reagents
        17.2.4. Others (Consumables, etc.)
    17.3. Market Attractiveness, by Product Type
    17.4. Market Value Forecast, by Test Type, 2020-2034
        17.4.1. Biopsy
        17.4.2. Imaging Tests
        17.4.3. Blood Tests
        17.4.4. Others (Genetic Testing, etc.)
    17.5. Market Attractiveness, by Test Type
    17.6. Market Value Forecast, By Cancer Stage, 2020-2034
        17.6.1. Stage 1
        17.6.2. Stage 2
        17.6.3. Stage 3
        17.6.4. Stage 4
    17.7. Market Attractiveness, By Cancer Stage
    17.8. Market Value Forecast, by Tumor Type, 2020-2034
        17.8.1. Renal Cell Carcinoma
        17.8.2. Clear Cell Carcinoma
        17.8.3. Non-clear Cell Carcinoma
    17.9. Market Attractiveness, by Tumor Type
    17.10. Market Value Forecast, by Technology, 2020-2034
        17.10.1. Fluorescent In Situ Hybridization
        17.10.2. Next Generation Sequencing
        17.10.3. Fluoroimmunoassay
        17.10.4. Comparative Genomic Hybridization
        17.10.5. Others (Immunohistochemical, etc.)
    17.11. Market Attractiveness, by Technology
    17.12. Market Value Forecast, by End-user, 2020-2034
        17.12.1. Hospitals
        17.12.2. Ambulatory Surgical Centers
        17.12.3. Nursing Centers
        17.12.4. Others (Long Term Care Centers, etc.)
    17.13. Market Attractiveness, by End-user
    17.14. Market Value Forecast, by Country/Sub-region, 2020-2034
        17.14.1. GCC Countries
        17.14.2. South Africa
        17.14.3. Rest of Middle East & Africa
    17.15. Market Attractiveness Analysis
        17.15.1. By Product Type
        17.15.2. By Test Type
        17.15.3. By Cancer Stage
        17.15.4. By Tumor Type
        17.15.5. By End-user
        17.15.6. By Country/Sub-region
18. Competition Landscape
    18.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    18.2. Market Share Analysis, by Company (2023)
    18.3. Company Profiles
        18.3.1. Siemens Healthineers
            18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.1.2. Product Portfolio
            18.3.1.3. Financial Overview
            18.3.1.4. SWOT Analysis
            18.3.1.5. Strategic Overview
        18.3.2. Koninklijke Philips N.V.
            18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.2.2. Product Portfolio
            18.3.2.3. Financial Overview
            18.3.2.4. SWOT Analysis
            18.3.2.5. Strategic Overview
        18.3.3. FUJIFILM Holdings Corporation
            18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.3.2. Product Portfolio
            18.3.3.3. Financial Overview
            18.3.3.4. SWOT Analysis
            18.3.3.5. Strategic Overview
        18.3.4. Grail
            18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.4.2. Product Portfolio
            18.3.4.3. Financial Overview
            18.3.4.4. SWOT Analysis
            18.3.4.5. Strategic Overview
        18.3.5. Laboratory Corporation of America Holdings
            18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.5.2. Product Portfolio
            18.3.5.3. Financial Overview
            18.3.5.4. SWOT Analysis
        18.3.6. Thermo Fisher Scientific
            18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.6.2. Product Portfolio
            18.3.6.3. Financial Overview
            18.3.6.4. SWOT Analysis
            18.3.6.5. Strategic Overview
        18.3.7. Myriad Genetics, Inc.
            18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.7.2. Product Portfolio
            18.3.7.3. Financial Overview
            18.3.7.4. SWOT Analysis
            18.3.7.5. Strategic Overview
        18.3.8. Canon Medical Systems Corporation
            18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.8.2. Product Portfolio
            18.3.8.3. Financial Overview
            18.3.8.4. SWOT Analysis
            18.3.8.5. Strategic Overview
        18.3.9. QIAGEN N.V.
            18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.9.2. Product Portfolio
            18.3.9.3. Financial Overview
            18.3.9.4. SWOT Analysis
            18.3.9.5. Strategic Overview
        18.3.10. Illumina, Inc.
            18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.10.2. Product Portfolio
            18.3.10.3. Financial Overview
            18.3.10.4. SWOT Analysis
            18.3.10.5. Strategic Overview
        18.3.11. Ambry Genetics
            18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.11.2. Product Portfolio
            18.3.11.3. Financial Overview
            18.3.11.4. SWOT Analysis
            18.3.11.5. Strategic Overview
        18.3.12. Invitae Corp.
            18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.12.2. Product Portfolio
            18.3.12.3. Financial Overview
            18.3.12.4. SWOT Analysis
            18.3.12.5. Strategic Overview
        18.3.13. Centogene N.V.
            18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            18.3.13.2. Product Portfolio
            18.3.13.3. Financial Overview
            18.3.13.4. SWOT Analysis
            18.3.13.5. Strategic Overview